The PPARγ agonist, rosiglitazone, attenuates airway inflammation and remodeling via heme oxygenase-1 in murine model of asthma

AIM: Rosiglitazone is one of the specific PPARγ agonists showing potential therapeutic effects in asthma. Though PPARγ activation was considered protective in inhibiting airway inflammation and remodeling in asthma, the specific mechanisms are still unclear. This study was aimed to investigate wheth...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Acta Pharmacol Sin
Huvudupphovsmän: Xu, Jing, Zhu, Yan-ting, Wang, Gui-zuo, Han, Dong, Wu, Yuan-yuan, Zhang, De-xin, Liu, Yun, Zhang, Yong-hong, Xie, Xin-ming, Li, Shao-jun, Lu, Jia-mei, Liu, Lu, Feng, Wei, Sun, Xiu-zhen, Li, Man-xiang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2015
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326789/
https://ncbi.nlm.nih.gov/pubmed/25619395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2014.128
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk